
Monia Guidi

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5468133/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Conformation-Specific Spectroscopy and Photodissociation of Cold, Protonated Tyrosine and Phenylalanine. Journal of the American Chemical Society, 2007, 129, 11814-11820.	6.6	195
2	Conformation-specific infrared and ultraviolet spectroscopy of tyrosine-based protonated dipeptides. Journal of Chemical Physics, 2007, 127, 154322.	1.2	80
3	The Steps to Therapeutic Drug Monitoring: A Structured Approach Illustrated With Imatinib. Frontiers in Pharmacology, 2020, 11, 177.	1.6	59
4	Effect of Single Nucleotide Polymorphisms in Cytochrome P450 Isoenzyme and <i>N</i> -Acetyltransferase 2 Genes on the Metabolism of Artemisinin-Based Combination Therapies in Malaria Patients from Cambodia and Tanzania. Antimicrobial Agents and Chemotherapy, 2013, 57, 950-958.	1.4	51
5	Population pharmacokinetic study of gentamicin in a large cohort of premature and term neonates. British Journal of Clinical Pharmacology, 2014, 78, 1090-1101.	1.1	50
6	Population pharmacokinetic approach to evaluate the effect of <i><scp>CYP2D6</scp>, <scp>CYP3A</scp>, <scp>ABCB1</scp>, <scp>POR</scp></i> and <i><scp>NR1I2</scp></i> genotypes on donepezil clearance. British Journal of Clinical Pharmacology, 2014, 78, 135-144.	1.1	46
7	Genetics-Based Population Pharmacokinetics and Pharmacodynamics of Risperidone in a Psychiatric Cohort. Clinical Pharmacokinetics, 2015, 54, 1259-1272.	1.6	44
8	Spectroscopy of Protonated Peptides Assisted by Infrared Multiple Photon Excitation. Journal of Physical Chemistry A, 2009, 113, 797-799.	1.1	43
9	Population Pharmacokinetic Study of Memantine: Effects of Clinical and Genetic Factors. Clinical Pharmacokinetics, 2013, 52, 211-223.	1.6	41
10	Effect of renal clearance and continuous renal replacement therapy on appropriateness of recommended meropenem dosing regimens in critically ill patients with susceptible life-threatening infections. Journal of Antimicrobial Chemotherapy, 2018, 73, 3413-3422.	1.3	40
11	Polypharmacy, Drug–Drug Interactions, and Inappropriate Drugs: New Challenges in the Aging Population With HIV. Open Forum Infectious Diseases, 2019, 6, ofz531.	0.4	38
12	Population Pharmacokinetics and Clinical Response for Artemether-Lumefantrine in Pregnant and Nonpregnant Women with Uncomplicated Plasmodium falciparum Malaria in Tanzania. Antimicrobial Agents and Chemotherapy, 2014, 58, 4583-4592.	1.4	37
13	Erlotinib. Therapeutic Drug Monitoring, 2015, 37, 2-21.	1.0	36
14	Population pharmacokinetics of mefloquine, piperaquine and artemether-lumefantrine in Cambodian and Tanzanian malaria patients. Malaria Journal, 2013, 12, 235.	0.8	33
15	Prediction of free imatinib concentrations based on total plasma concentrations in patients with gastrointestinal stromal tumours. British Journal of Clinical Pharmacology, 2013, 75, 1007-1018.	1.1	33
16	Population Pharmacokinetics and Pharmacogenetics Analysis of Rilpivirine in HIV-1-Infected Individuals. Antimicrobial Agents and Chemotherapy, 2017, 61, .	1.4	32
17	Population pharmacokinetic modelling and evaluation of different dosage regimens for darunavir and ritonavir in HIV-infected individuals. Journal of Antimicrobial Chemotherapy, 2014, 69, 2489-2498.	1.3	31
18	Relationship of CYP2D6, CYP3A, POR, and ABCB1 Genotypes With Galantamine Plasma Concentrations. Therapeutic Drug Monitoring, 2013, 35, 270-275.	1.0	27

Monia Guidi

#	Article	IF	CITATIONS
19	High-throughput hydrophilic interaction chromatography coupled to tandem mass spectrometry for the optimized quantification of the anti-Gram-negatives antibiotic colistin A/B and its pro-drug colistimethate. Journal of Chromatography A, 2014, 1369, 52-63.	1.8	26
20	Population Genetic-Based Pharmacokinetic Modeling of Methadone and its Relationship with the QTc Interval in Opioid-Dependent Patients. Clinical Pharmacokinetics, 2016, 55, 1521-1533.	1.6	25
21	Optimisation of vancomycin exposure in neonates based on the best level of evidence. Pharmacological Research, 2020, 154, 104278.	3.1	25
22	Therapeutic Drug Monitoring of Targeted Anticancer Protein Kinase Inhibitors in Routine Clinical Use: A Critical Review. Therapeutic Drug Monitoring, 2020, 42, 33-44.	1.0	25
23	Pharmacogenetics-based population pharmacokinetic analysis of etravirine in HIV-1 infected individuals. Pharmacogenetics and Genomics, 2013, 23, 9-18.	0.7	25
24	Population pharmacokinetics of dolutegravir: influence of drug–drug interactions in a real-life setting. Journal of Antimicrobial Chemotherapy, 2019, 74, 2690-2697.	1.3	23
25	Pharmacokinetic profiles of boosted darunavir, dolutegravir and lamivudine in aging people living with HIV. Aids, 2020, 34, 103-108.	1.0	18
26	Parametric Approaches in Population Pharmacokinetics. Journal of Clinical Pharmacology, 2022, 62, 125-141.	1.0	17
27	Population pharmacokinetic analysis of elvitegravir and cobicistat in HIV-1-infected individuals. Journal of Antimicrobial Chemotherapy, 2016, 71, 1933-1942.	1.3	13
28	A population pharmacokinetic model for escitalopram and its major metabolite in depressive patients during the perinatal period: Prediction of infant drug exposure through breast milk. British Journal of Clinical Pharmacology, 2020, 86, 1642-1653.	1.1	13
29	Population Pharmacokinetics of Erlotinib in Patients With Non–small Cell Lung Cancer: Its Application for Individualized Dosing Regimens in Older Patients. Clinical Therapeutics, 2020, 42, 1302-1316.	1.1	13
30	Population Pharmacokinetics/Pharmacodynamics of Dabrafenib Plus Trametinib in Patients with BRAF-Mutated Metastatic Melanoma. Cancers, 2020, 12, 931.	1.7	12
31	Some Properties of Lysozymeâ^'Lithium Perfluorononanoate Complexes. Biomacromolecules, 2007, 8, 399-405.	2.6	11
32	Population pharmacokinetics and pharmacodynamics of the artesunate–mefloquine fixed dose combination for the treatment of uncomplicated falciparum malaria in African children. Malaria Journal, 2019, 18, 139.	0.8	10
33	Phase I Dose-Escalation Study of the Dual PI3K-mTORC1/2 Inhibitor Gedatolisib in Combination with Paclitaxel and Carboplatin in Patients with Advanced Solid Tumors. Clinical Cancer Research, 2021, 27, 5012-5019.	3.2	10
34	Parametric and Nonparametric Methods in Population Pharmacokinetics: Experts' Discussion on Use, Strengths, and Limitations. Journal of Clinical Pharmacology, 2022, 62, 158-170.	1.0	9
35	Dosage Optimization of Treatments Using Population Pharmacokinetic Modeling and Simulation. Chimia, 2012, 66, 291-295.	0.3	8
36	Amisulpride: Real-World Evidence of Dose Adaptation and Effect on Prolactin Concentrations and Body Weight Gain by Pharmacokinetic/Pharmacodynamic Analyses. Clinical Pharmacokinetics, 2020, 59, 371-382.	1.6	8

Monia Guidi

#	Article	IF	CITATIONS
37	Sultiame pharmacokinetic profile in plasma and erythrocytes after single oral doses: A pilot study in healthy volunteers. Pharmacology Research and Perspectives, 2020, 8, e00558.	1.1	8
38	Elevated acute phase proteins affect pharmacokinetics in COVIDâ€19 trials: Lessons from the CounterCOVID ―imatinib study. CPT: Pharmacometrics and Systems Pharmacology, 2021, 10, 1497-1511.	1.3	8
39	Cascaded PID controller for anaesthesia delivery. , 2016, 2016, 533-536.		7
40	Robustness analysis of personalised delivery rate computation for IV administered anesthetic. Smart Health, 2018, 9-10, 101-114.	2.0	7
41	Escitalopram population pharmacokinetics in people living with human immunodeficiency virus and in the psychiatric population: Drug–drug interactions and probability of target attainment. British Journal of Clinical Pharmacology, 2019, 85, 2022-2032.	1.1	7
42	Impact of Genetic and Nongenetic Factors on Body Mass Index and Waist-Hip Ratio Change in HIV-Infected Individuals Initiating Antiretroviral Therapy. Open Forum Infectious Diseases, 2020, 7, ofz464.	0.4	7
43	Vitamin D Time Profile Based on the Contribution of Non-Genetic and Genetic Factors in HIV-Infected Individuals of European Ancestry. Antiviral Therapy, 2015, 20, 261-269.	0.6	5
44	Influence of Drug–Drug Interactions on the Pharmacokinetics of Atorvastatin and Its Major Active Metabolite ortho-OH-Atorvastatin in Aging People Living with HIV. Clinical Pharmacokinetics, 2020, 59, 1037-1048.	1.6	5
45	Population Pharmacokinetic Models for Direct Oral Anticoagulants: A Systematic Review and Clinical Appraisal Using Exposure Simulation. Clinical Pharmacology and Therapeutics, 2022, 112, 353-363.	2.3	5
46	Pharmacokinetic/Pharmacodynamic Modelling to Describe the Cholesterol Lowering Effect of Rosuvastatin in People Living with HIV. Clinical Pharmacokinetics, 2021, 60, 379-390.	1.6	4
47	Modelâ€based metaâ€analysis of salbutamol pharmacokinetics and practical implications for doping control. CPT: Pharmacometrics and Systems Pharmacology, 2022, , .	1.3	4
48	Adherence to intermittent preventive treatment for malaria in Papua New Guinean infants: A pharmacological study alongside the randomized controlled trial. PLoS ONE, 2019, 14, e0210789.	1.1	3
49	Enantiospecific pharmacokinetics of intravenous dexmedetomidine in beagles. Journal of Veterinary Pharmacology and Therapeutics, 2022, , .	0.6	3
50	Population Pharmacokinetics of Palbociclib and Its Correlation with Clinical Efficacy and Safety in Patients with Advanced Breast Cancer. Pharmaceutics, 2022, 14, 1317.	2.0	3
51	Influence of body weight and UGT2B7 polymorphism on varenicline exposure in a cohort of smokers from the general population. European Journal of Clinical Pharmacology, 2019, 75, 939-949.	0.8	2
52	Population pharmacokinetic modelling to quantify the magnitude of drug-drug interactions between amlodipine and antiretroviral drugs. European Journal of Clinical Pharmacology, 2021, 77, 979-987.	0.8	2
53	Dosing strategies of imipenem in neonates based on pharmacometric modelling and simulation. Journal of Antimicrobial Chemotherapy, 2021, , .	1.3	2
54	Methods for Personalised Delivery Rate Computation for IV Administered Anesthetic Propofol. Computational Biology, 2019, , 369-397.	0.1	1

#	Article	IF	CITATION
55	Pharmacokinetic parameters and weight change in HIV patients newly switched to dolutegravirâ€based regimens in SIMPL'HIV clinical trial. British Journal of Clinical Pharmacology, 2021, 87, 4455-4460.	1.1	0